Physician profile
Robert S Lindgren
NPI 1518427418
$2,699.16
in general payments reported to CMS, 2019-2025
21 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $542 · 2023: $1,235 · 2024: $682 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $394.78 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $359.09 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $350.07 | 2022-2024 | Farxiga, Breztri, Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $330.09 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $241.65 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $180.15 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.51 | 2022-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $125.05 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $110.42 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $94.64 | 2024-2025 | Rexulti |
| Amgen INC. | $83.22 | 2022-2024 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $65.27 | 2022-2025 | Spravato, Xarelto |
| Exact Sciences Corporation | $64.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $24.14 | 2023 | Accrufer |
| Abbott Laboratories | $23.17 | 2023 | Freestyle Libre 3 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.09 | 2024 | Veozah |
| Radius Health, INC. | $20.75 | 2025 | Tymlos |
| Corcept Therapeutics | $18.88 | 2025 | Korlym |
| Currax Pharmaceuticals LLC | $14.50 | 2025 | Contrave |
| Esperion Therapeutics, INC. | $14.03 | 2025 | Nexletol |
| Ibsa Pharma INC. | $13.76 | 2025 | Flector, Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lindgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.